The purpose of this study is to compare the usual treatment used most frequently, which is cytarabine and daunorubicin alone, to two new approaches: adding venetoclax to cytarabine and daunorubicin and adding venetoclax to another chemotherapy drug called azacitidine.
Learn more about the MyeloMATCH MM1YA-CTG01 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
